Baroda BNP Paribas Small Cap Fund
The Scheme seeks to generate long-term capital appreciation by investing predominantly in equity and equity related securities of small cap companies.
Growthvine rating: 3/5 — ranked #18 of 37 in category.
Fund basics
| Category | Equity: Small Cap |
|---|
| NAV | ₹14.12 (as of 2026-11-13) |
|---|
| AUM | ₹1,277 Cr |
|---|
| Expense ratio | 1.85% |
|---|
| Riskometer | Very High |
|---|
| Fund manager | Himanshu Singh |
|---|
| Exit load | For units in excess of 10% of the investment, 1% will be charged for redemption within 1 year |
|---|
Performance & risk
| Standard deviation | 0.00% |
|---|
| Max drawdown | −25.37% |
|---|
| Alpha | 0 |
|---|
| Beta | 0 |
|---|
Over 5 years, captured 83.4% of NIFTY Smallcap 250's upside and 82.4% of its downside.
Market cap allocation
| Large cap | 6.0% |
|---|
| Mid cap | 13.9% |
|---|
| Small cap | 80.2% |
|---|
Concentration
| Top 5 holdings | 18.2% |
|---|
| Top 10 holdings | 31.5% |
|---|
| Total holdings | 64 |
|---|
| Index overlap | 22.0% |
|---|
| Active share | 78.0% |
|---|
Top holdings
- Clearing Corporation of India Ltd — 5.6%
- Karur Vysya Bank Ltd. — 4.4%
- Laurus Labs Limited — 4.1%
- Navin Fluorine International Limited — 3.4%
- Multi Commodity Exchange of India Ltd — 3.4%
- Physicswallah Limited — 2.9%
- Bharat Heavy Electricals Ltd. — 2.9%
- ACUTAAS CHEMICALS LIMITED — 2.6%
- Emcure Pharmaceuticals Limited — 2.6%
- Dr. Lal Pathlabs Limited — 2.6%
Top sectors
- Banking & Financial — 13.2%
- Pharma & Biotech — 13.2%
- Automobile — 8.9%
Calendar-year track record
| Year | Return | Quartile | Category rank |
|---|
| 2026 (partial) | 9.7% | Q3 | #21 of 34 |
| 2025 | −6.6% | Q3 | #23 of 30 |
| 2024 | 24.4% | Q3 | #17 of 28 |